"Vaccines Market Will Reach $33.8 Billion in 2012" Visiongain Report Predicts
A new report by visiongain predicts that the 2012 world market for vaccines to treat human beings will reach $33.8 billion. That revenue forecast appears in World Vaccines Market 2012-2022, published in July 2012. Visiongain is a business information provider based in London, UK.
London, United Kingdom, July 27, 2012 --(PR.com)-- Paediatric vaccination is the traditional cornerstone of the market, and this segment continues to dominate, with the forthcoming release of Bexsero (Novartis’ vaccine against meningitis B) set to enlarge the market. However, increased vaccination of adults and growing penetration of therapeutic vaccines in the cancer treatment market will drive the next phase of growth through to 2022, the study notes.
Dr James Evans, a pharmaceutical industry analyst in visiongain, said: “Pfizer’s Prevnar-13, the biggest vaccine franchise in the world in 2011 with sales of $3.7bn, is soon to be extended to adults. It’s the first multi-billion dollar vaccine franchise, and it will replace Lipitor as Pfizer’s biggest product.
“That’s a symbolic moment: vaccines are joining other biological products as the main driver for the pharmaceutical industry overall. The expansion of the therapeutic vaccines segment will accelerate that process, with vaccine treatments for melanoma, ovarian and lung cancers in the next ten years.”
Visiongain’s report provides revenue forecasts to 2022 at overall world market, submarket, product and national level. It forecasts the following world-level submarkets:
• Paediatric vaccines
• Influenza vaccines
• Adult prophylactic vaccines
• Therapeutic vaccines.
The investigation predicts revenues of leading vaccines, including Prevnar-13, Pentacel, Gardasil and Fluzone. Research, data and analyses cover activities of Sanofi Pasteur, Pfizer, GlaxoSmithKline, Merck and other vaccine developers and manufacturers.
That study discusses R&D and commercial news, shows research interviews and forecasts revenues in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain and Italy (EU5), Brazil, Russia, India and China (BRIC).
World Vaccines Market 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the Visiongain report World Vaccines Market 2012-2022 please visit: http://www.visiongain.com/Report/859/World-Vaccines-Market-2012-2022
For an executive summary of this report or to order it today please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Dr James Evans, a pharmaceutical industry analyst in visiongain, said: “Pfizer’s Prevnar-13, the biggest vaccine franchise in the world in 2011 with sales of $3.7bn, is soon to be extended to adults. It’s the first multi-billion dollar vaccine franchise, and it will replace Lipitor as Pfizer’s biggest product.
“That’s a symbolic moment: vaccines are joining other biological products as the main driver for the pharmaceutical industry overall. The expansion of the therapeutic vaccines segment will accelerate that process, with vaccine treatments for melanoma, ovarian and lung cancers in the next ten years.”
Visiongain’s report provides revenue forecasts to 2022 at overall world market, submarket, product and national level. It forecasts the following world-level submarkets:
• Paediatric vaccines
• Influenza vaccines
• Adult prophylactic vaccines
• Therapeutic vaccines.
The investigation predicts revenues of leading vaccines, including Prevnar-13, Pentacel, Gardasil and Fluzone. Research, data and analyses cover activities of Sanofi Pasteur, Pfizer, GlaxoSmithKline, Merck and other vaccine developers and manufacturers.
That study discusses R&D and commercial news, shows research interviews and forecasts revenues in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain and Italy (EU5), Brazil, Russia, India and China (BRIC).
World Vaccines Market 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the Visiongain report World Vaccines Market 2012-2022 please visit: http://www.visiongain.com/Report/859/World-Vaccines-Market-2012-2022
For an executive summary of this report or to order it today please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Contact
Visiongain
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Contact
Categories